Dendreon
Headquarters country
United States
Registry sponsor category
Industry
- Other names
- Dendreon
- Company name
- Dendreon
- Organisation type
- Industry
- Registered legal name
- Dendreon Corporation
- Registry sponsor category
- Industry
- Legal Entity Identifier (LEI)
- 549300C0XK81HDI8KK82
Related records
Trials (31)
- A Multicenter Trial Enrolling Men With Advanced Prostate Cancer Who Are to Receive Combination Radiation and Sipuleucel-T
- A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
- A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
- Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer
- Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer
- DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
- Dose Escalation Study of EC D-3263 HCl in Advanced Solid Tumors
- Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T
- Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442)
- Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer
- Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
- Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer
- Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer
- PET/MR Assessment of Sipuleucel T Treatment for Metastatic Castration Resistant Prostate Cancer
- Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer
- PROvenge Treatment and Early Cancer Treatment
- Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer
- Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy
- Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T
- Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer